PD-1抑制剂联合治疗晚期肺鳞癌疗效及预后的相关独立因素分析

打开文本图片集

关键词：肺鳞癌； PD-1 抑制剂；独立因素 中图分类号：R734.2 文章编号：1006-1959（2026）04-0113-05 文献标识码：A DOI：10.3969/j.issn.1006-1959.2026.04.019

Abstract：ObjectieTexplorthedependentfctorselatedtotfcacydrogosisofD-inbitorcombiedihimuotapn thetreatmntfdacdungsuamouscellarcioa（LUSC）MethosTataof4patientitdvaedLUSCtreatedit immunotherapyinFuyangPeople'sHospitalofAhuMedicalUniversityfromMarch2O2OtoOctober2O24wereretrospectivelyanalyzed. Univariateaduivaatelssedtoaleaediepeetiatitcdprogoofa ResultsAfter 2 cycles of treatment，the objective response rate（ORR） was 39.42% ，and the disease control rate（DCR） was 92.31% .Univariate analysisot PFS in LUSC patients treated with PD-1 inhibitor immunotherapy（ P <0.05），while age，gender，smoking history，multiple organ metastasis，liver metastasis，eassisdoatorcale，，，Ldeed （P>0.05） Multivariate COX regression analysis showed that maintenance therapy（HR=6.317，95 %Cl. 3.397-11.748，P=0.000），ECOG PS sc0re （HR=0.196， 95%CI0.05170ndD（H299，95%C465ereidepeentfactosetigSinUs treatedwithD-iiosConusionomainteancetapyigndigCOGorearessocatedwitoosisin patientswithdvacedUSCtreatedith-iiosainteacetrayCOGSsoendDlvelareidependentfactfein efficacy and prognosis.

Keywords：Lung squamouscell carcinoma;PD-1 inhibitors; Independent factors

肺癌（lungcancer）是我国恶性肿瘤中发病与死亡负担最重的疾病类型，2020年全球癌症报告显示，该病在全球范围内新发病例占比达 11.4% ，致死率高达 18% ，居各类癌症之首。（剩余8370字）